Thomas Shrader
Stock Analyst at BTIG
(3.72)
# 2,878
Out of 5,182 analysts
93
Total ratings
50.57%
Success rate
8.11%
Average return
Main Sectors:
Stocks Rated by Thomas Shrader
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HROW Harrow | Reiterates: Buy | $63 | $40.16 | +56.87% | 5 | Apr 17, 2026 | |
| DRUG Bright Minds Biosciences | Reiterates: Buy | $147 | $89.45 | +64.34% | 5 | Mar 30, 2026 | |
| ABOS Acumen Pharmaceuticals | Reiterates: Buy | $8 | $2.87 | +178.75% | 5 | Mar 26, 2026 | |
| OVID Ovid Therapeutics | Reiterates: Buy | $4 | $2.91 | +37.46% | 4 | Mar 26, 2026 | |
| DNLI Denali Therapeutics | Maintains: Buy | $36 → $38 | $20.57 | +84.74% | 6 | Mar 25, 2026 | |
| NRXP NRx Pharmaceuticals | Reiterates: Buy | $25 | $2.93 | +753.24% | 4 | Mar 24, 2026 | |
| STOK Stoke Therapeutics | Reiterates: Buy | $39 | $36.19 | +7.76% | 3 | Mar 19, 2026 | |
| ACIU AC Immune | Reiterates: Buy | $8 | $2.97 | +169.47% | 4 | Mar 16, 2026 | |
| ALEC Alector | Upgrades: Buy | $6 | $2.64 | +127.70% | 5 | Mar 10, 2026 | |
| IRD Opus Genetics | Maintains: Buy | $7 → $12 | $5.34 | +124.72% | 3 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $1.68 | +495.24% | 3 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $85 → $89 | $62.55 | +42.29% | 7 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $27 → $28 | $27.25 | +2.75% | 2 | Feb 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $19 | $8.70 | +118.39% | 1 | Jan 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $16 | $10.76 | +48.70% | 5 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $16 | $4.77 | +235.43% | 3 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $9 | $1.80 | +400.00% | 2 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $48 → $23 | $8.82 | +160.77% | 2 | Oct 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $9 | $2.15 | +319.58% | 4 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $14 | $8.96 | +56.25% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.42 | - | 3 | Jul 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $200 | $11.90 | +1,581.38% | 1 | Oct 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $180 → $60 | $7.81 | +668.25% | 1 | Jul 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $7 | $6.47 | +8.19% | 2 | May 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $3,400 → $650 | $4.93 | +13,084.58% | 3 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $51 | $1.31 | +3,793.13% | 1 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $5.10 | +214.03% | 1 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.25 | - | 1 | Feb 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $3 | $1.61 | +86.92% | 3 | Apr 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $397 → $346 | $182.90 | +89.17% | 3 | Feb 21, 2019 |
Harrow
Apr 17, 2026
Reiterates: Buy
Price Target: $63
Current: $40.16
Upside: +56.87%
Bright Minds Biosciences
Mar 30, 2026
Reiterates: Buy
Price Target: $147
Current: $89.45
Upside: +64.34%
Acumen Pharmaceuticals
Mar 26, 2026
Reiterates: Buy
Price Target: $8
Current: $2.87
Upside: +178.75%
Ovid Therapeutics
Mar 26, 2026
Reiterates: Buy
Price Target: $4
Current: $2.91
Upside: +37.46%
Denali Therapeutics
Mar 25, 2026
Maintains: Buy
Price Target: $36 → $38
Current: $20.57
Upside: +84.74%
NRx Pharmaceuticals
Mar 24, 2026
Reiterates: Buy
Price Target: $25
Current: $2.93
Upside: +753.24%
Stoke Therapeutics
Mar 19, 2026
Reiterates: Buy
Price Target: $39
Current: $36.19
Upside: +7.76%
AC Immune
Mar 16, 2026
Reiterates: Buy
Price Target: $8
Current: $2.97
Upside: +169.47%
Alector
Mar 10, 2026
Upgrades: Buy
Price Target: $6
Current: $2.64
Upside: +127.70%
Opus Genetics
Mar 2, 2026
Maintains: Buy
Price Target: $7 → $12
Current: $5.34
Upside: +124.72%
Feb 26, 2026
Reiterates: Buy
Price Target: $10
Current: $1.68
Upside: +495.24%
Feb 26, 2026
Maintains: Buy
Price Target: $85 → $89
Current: $62.55
Upside: +42.29%
Feb 17, 2026
Maintains: Buy
Price Target: $27 → $28
Current: $27.25
Upside: +2.75%
Jan 20, 2026
Reiterates: Buy
Price Target: $19
Current: $8.70
Upside: +118.39%
Nov 18, 2025
Reiterates: Buy
Price Target: $16
Current: $10.76
Upside: +48.70%
Nov 13, 2025
Maintains: Buy
Price Target: $15 → $16
Current: $4.77
Upside: +235.43%
Nov 10, 2025
Reiterates: Buy
Price Target: $9
Current: $1.80
Upside: +400.00%
Oct 22, 2025
Maintains: Buy
Price Target: $48 → $23
Current: $8.82
Upside: +160.77%
Oct 15, 2025
Reiterates: Buy
Price Target: $9
Current: $2.15
Upside: +319.58%
Oct 13, 2025
Maintains: Buy
Price Target: $7 → $14
Current: $8.96
Upside: +56.25%
Jul 1, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.42
Upside: -
Oct 3, 2023
Initiates: Buy
Price Target: $200
Current: $11.90
Upside: +1,581.38%
Jul 28, 2023
Maintains: Buy
Price Target: $180 → $60
Current: $7.81
Upside: +668.25%
May 25, 2023
Maintains: Buy
Price Target: $15 → $7
Current: $6.47
Upside: +8.19%
Mar 28, 2023
Maintains: Buy
Price Target: $3,400 → $650
Current: $4.93
Upside: +13,084.58%
Apr 20, 2021
Initiates: Buy
Price Target: $51
Current: $1.31
Upside: +3,793.13%
Mar 8, 2021
Initiates: Buy
Price Target: $16
Current: $5.10
Upside: +214.03%
Feb 3, 2021
Downgrades: Neutral
Price Target: n/a
Current: $4.25
Upside: -
Apr 3, 2020
Maintains: Buy
Price Target: $4 → $3
Current: $1.61
Upside: +86.92%
Feb 21, 2019
Downgrades: Hold
Price Target: $397 → $346
Current: $182.90
Upside: +89.17%